Natriuretic peptide dynamics predict long-term outcomes after TAVI
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Abstract Background Identification of high-risk individuals after transcatheter aortic valve implantation (TAVI) is essential for personalized care. Circulating brain natriuretic peptide (BNP) or N-terminal pro–B-type natriuretic peptide (NT-proBNP) reflect myocardial stress, yet the prognostic implication of their longitudinal trajectories have not been fully characterized. Purpose We aimed to evaluate the association between BNP or NT-proBNP dynamics with long-term all-cause mortality following TAVI in two independent large cohorts. Methods Patients undergoing TAVI at a high-volume university centre in the United Kingdom (UK; n = 990) were recruited into this prospective cohort study. Patient characteristics along with pre- and post-procedural imaging results and BNP levels before the procedure and at 3-12 months after the procedure were recorded. An independent cohort of 1,793 patients undergoing TAVI at a high-volume university hospital in Switzerland between January 2008 and May 2024 was also included, with a median follow-up of 4.0 years (IQR 2.2–5.6). In this cohort, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was measured at baseline and at 2 weeks after the procedure. Patients were categorized according to natriuretic peptide trajectories (low/low, high/low, low/high, high/high). Long-term all-cause mortality was assessed using Kaplan–Meier estimates and multivariable-adjusted Cox regression. Results During median follow-up of 5.3 years (UK) and 4.0 years (Switzerland), 414 (41.8%) and 796 (44.4%) all-cause deaths occurred, respectively. In the UK cohort, longitudinal changes in BNP using a threshold of 400 pg/mL were independently associated with long-term mortality (high/low vs. low/low: adjusted hazard ratio [adj HR] 1.25, 95% CI 0.75–2.09, P = 0.397; high/high vs. low/low: adj HR 1.91, 95% CI 1.05–3.46, P = 0.033). Similarly, in the Swiss cohort, early post-procedural changes in NT-proBNP using a threshold of 1800 pg/mL predicted higher long-term mortality (high/low vs. low/low: adj HR 1.23, 95% CI 0.80–1.90, P = 0.336; high/high vs. low/low: adj HR 1.91, 95% CI 1.38–2.64, P < 0.001). Cumulative incidence curves demonstrated significant differences in mortality across trajectory groups in both cohorts. Conclusion Natriuretic peptide trajectories independently predicted long-term mortality after TAVI. Patients with persistently elevated BNP or NT-proBNP are at particularly high mortality risk. Serial assessment may enhance post-TAVI risk stratification and guide personalized management.Cumulative incidence of mortalityFor image description, please refer to the figure legend and surrounding text.
Fields of Study & Subjects
Cardiac Valve Diseases and Treatments
Aortic Disease and Treatment Approaches
Infective Endocarditis Diagnosis and Management
Publication details
- Journal / source
- European Heart Journal Supplements
- Volume
- 28
- Issue
- Supplement_3
- Publication date
- 1 March 2026
- Language
- EN